Can blood tests predict liver Cancer's return?
NCT ID NCT06141564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting blood and tissue samples from 360 people with early-stage liver cancer who have had surgery to remove their tumors. Researchers want to find biological markers that could predict if the cancer will come back. The goal is to better understand the immune system's role in recurrence and eventually improve treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients are at high risk of liver cancer returning after surgery, and guide more personalized immunotherapy.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead directly to new therapies, and the findings might not apply to all liver cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
108 Military Central Hospital
Hanoi, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?